

NOTICE: For the convenience of capital market participants, Chugai makes efforts to provide English translations of the information disclosed in Japanese, provided that the Japanese original prevails over its English translation in the case of any discrepancy found between documentation.



**CHUGAI PHARMACEUTICAL CO., LTD.**

A member of the Roche group

## CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)

(for the third quarter of the fiscal year 2017)

Name of Company: Chugai Pharmaceutical Co., Ltd. October 25, 2017  
 Stock Listing: Tokyo Stock Exchange  
 Security Code No.: 4519 (URL <https://www.chugai-pharm.co.jp/english>)  
 Representative: Osamu Nagayama, Representative Director, Chairman and CEO  
 Contact: Masahiko Uchida, General Manager of Corporate Communications Department  
 Phone: +81-(0)3-3273-0881  
 Date of Submission of Quarterly Marketable Securities Filings: October 30, 2017  
 Date on which Dividend Payments to Commence: —  
 Supplementary Materials Prepared for the Quarterly Financial Statements: Yes  
 Presentation Held to Explain the Quarterly Financial Statements: Yes (for institutional investors and securities analysts)

*(Note: Amounts of less than one million yen are rounded.)*

### 1. Consolidated results for the third quarter of FY 2017 (January 1, 2017–September 30, 2017)

#### (1) Consolidated operating results

	Revenues	% change	Operating profit	% change	Profit before taxes	% change
First nine months of FY 2017	¥387,645 million	7.2	¥76,233 million	30.0	¥74,853 million	26.7
First nine months of FY 2016	¥361,517 million	(1.7)	¥58,635 million	(12.6)	¥59,059 million	(12.4)

	Net income	% change	Net income attributable to Chugai shareholders	% change	Total comprehensive income	% change
First nine months of FY 2017	¥57,851 million	32.4	¥57,196 million	32.8	¥58,177 million	61.7
First nine months of FY 2016	¥43,702 million	(10.0)	¥43,084 million	(9.6)	¥35,980 million	(20.9)

	Earnings per share (Basic)	Earnings per share (Diluted)
First nine months of FY 2017	¥104.66	¥104.51
First nine months of FY 2016	¥78.89	¥78.77

Notes: 1. Percentages represent changes compared with the same period of the previous fiscal year.

2. The item "Attributable to Chugai shareholders" excludes the portion attributable to non-controlling interests.

#### (2) Consolidated results (balance sheet)

	Total assets	Total equity	Equity attributable to Chugai shareholders	Ratio of equity attributable to Chugai shareholders
As of Sep. 30, 2017	¥817,945 million	¥674,558 million	¥673,772 million	82.4%
As of Dec. 31, 2016	¥806,285 million	¥646,497 million	¥645,508 million	80.1%

Note: The item "Attributable to Chugai shareholders" excludes the portion attributable to non-controlling interests.

## 2. Dividends

	Annual dividends per share				
	End of first quarter	End of second quarter	End of third quarter	End of fiscal year	Total
FY ended Dec. 2016	—	¥26.00	—	¥26.00	¥52.00
FY ending Dec. 2017	—	¥29.00	—		
FY ending Dec. 2017 (Forecast)				¥29.00	¥58.00

Notes: Whether the most recent dividend forecast has been revised: No

## 3. Consolidated forecasts for FY 2017 (January 1, 2017–December 31, 2017)

	Revenues	% change	Core operating profit	% change	Core earnings per share		Core dividend payout ratio %
First nine months of FY 2017 (Results)	¥387,645 million	74.5	¥78,659 million	85.5	¥107.80	86.9	—
FY ending Dec. 2017 (Forecast)	¥520,500 million	5.8	¥92,000 million	14.2	¥124.11	21.1	46.7

Notes: 1. Percentages shown for forecasts of revenues, Core operating profit and Core EPS represent changes from the same period of the previous fiscal year. Percentages for results represent the percentage of forecast levels that have been achieved to date.

2. Whether the most recent forecasts for consolidated figures have been revised: No

3. The figures for the consolidated forecasts and actuals are calculated based on Core basis indicators established by Chugai Pharmaceutical Co., Ltd. ("Chugai") and used on a consistent basis. Core EPS is diluted earnings per share attributable to Chugai shareholders on a Core basis.

## 4. Others

(1) Changes in the state of material subsidiaries during the period (Changes in the state of specific subsidiaries with change in scope of consolidation): None

(2) Changes in accounting policies and changes in accounting estimates

(a) Changes in accounting policies required by IFRS: None

(b) Changes in accounting policies other than those in (a) above: None

(c) Changes in accounting estimates: None

(3) Number of shares issued (common stock):

(a) Number of shares issued at the end of the period (including treasury stock)

As of Sep. 30, 2017	559,685,889	As of Dec. 31, 2016	559,685,889
As of Sep. 30, 2017	13,035,399	As of Dec. 31, 2016	13,417,953
First nine months of FY 2017	546,484,377	First nine months of FY 2016	546,159,637

(b) Number of treasury stock at the end of the period

(c) Average number of shares issued during the period (nine months)

Notes:

**The quarterly financial statements are not subject to quarterly reviews.**

### Explanation of the appropriate use of performance forecasts and other related items

(1) Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may differ from these forecasts due to potential risks and uncertainties.

(2) The forecast which is published for shareholders and investors is based on the internal management indicator Core basis under International Financial Reporting Standards ("IFRS"). The difference between IFRS results and Core results will be explained at each event and presentation.

(3) For the specifics of the forecasts, please refer to "Forecast for consolidated performance" on page 5 of the attached document.

(4) Chugai is scheduled to hold a conference call for investors as noted below. The materials used for the call, the verbal recording, the Q&A, and other related documents will be posted on the Chugai's website following the conclusion of the conference call. Teleconference for institutional investors and securities analysts (Japanese only): October 25, 2017, Wednesday (Japan time). The English translation of the conference materials will be posted on the website on the next business day.

**Index of the Attachment**

**1. Qualitative Information ..... 2**

- (1) Consolidated operating results ..... 2
- (2) Consolidated financial position ..... 4
- (3) Forecast for consolidated performance ..... 5

**2. Interim Condensed Consolidated Financial Statements and Major Notes ..... 6**

- (1) Interim condensed consolidated income statement and interim condensed consolidated statement of comprehensive income ..... 6
- (2) Interim condensed consolidated balance sheet ..... 8
- (3) Interim condensed consolidated statement of cash flows ..... 9
- (4) Interim condensed consolidated statement of changes in equity ..... 10
- (5) Notes regarding the going concern assumption ..... 11
- (6) Notes regarding the interim condensed consolidated financial statements ..... 11

## 1. Qualitative Information

### (1) Consolidated operating results in billions of yen

	First nine months of FY 2017.12 (Jan. 1, 2017–Sep. 30, 2017)	First nine months of FY 2016.12 (Jan. 1, 2016–Sep. 30, 2016)	% change
<b>Core results</b>			
<b>Revenues</b>	<b>387.6</b>	<b>361.5</b>	<b>+7.2</b>
Sales (excluding Tamiflu)	354.8	339.1	+4.6
Tamiflu sales	10.0	8.4	+19.0
Royalties and other operating income	22.9	14.0	+63.6
Cost of sales	(185.6)	(183.0)	+1.4
<b>Gross profit</b>	<b>202.1</b>	<b>178.6</b>	<b>+13.2</b>
Marketing and distribution	(49.2)	(49.9)	(1.4)
Research and development	(63.2)	(60.2)	+5.0
General and administration	(11.0)	(8.9)	+23.6
<b>Operating profit</b>	<b>78.7</b>	<b>59.6</b>	<b>+32.0</b>
<b>Net income</b>	<b>59.7</b>	<b>44.3</b>	<b>+34.8</b>
<b>IFRS results</b>			
Revenues	387.6	361.5	+7.2
Operating profit	76.2	58.6	+30.0
Net income	57.9	43.7	+32.5

#### Consolidated financial highlights (IFRS results)

Revenues for the nine months under review were ¥387.6 billion (an increase of 7.2% year on year), operating profit for the nine months under review was ¥76.2 billion (an increase of 30.0% year on year), and net income for the nine months under review was ¥57.9 billion (an increase of 32.5% year on year). These results include non-Core items, such as amortization of intangible assets of ¥0.9 billion, impairment loss of intangible assets of ¥2.5 billion and gain on litigation of ¥1.0 billion received as compensation, etc. associated with the Oxarol lawsuit, which are excluded from the Core results that Chugai adopts to manage recurring business activities.

#### Consolidated financial highlights (Core results)

Revenues for the nine months under review were ¥387.6 billion (an increase of 7.2% year on year), due to increases in sales and royalties and other operating income.

Of revenues, sales excluding Tamiflu were ¥354.8 billion (an increase of 4.6% year on year), due to the sales growth in the bone and joint diseases area and increases in Alecensa and Actemra exports to Roche, despite the effects of the previous year's NHI drug price revisions in the first quarter. Royalties and other operating income amounted to ¥22.9 billion (an increase of 63.6% year on year), due to an increase of one-time income such as milestone income.

Cost to sales ratio was 50.9%, a 1.8 percentage point improvement year on year, due to a change in the product mix, etc. As a result, gross profit amounted to ¥202.1 billion (an increase of 13.2% year on year).

Operating expenses were ¥123.4 billion (an increase of 3.7% year on year). Marketing and distribution expenses were ¥49.2 billion (a decrease of 1.4% year on year) due to the reclassification of some expenses due to organizational changes, etc. On the other hand, research and development expenses amounted to ¥63.2 billion (an increase of 5.0% year on year), due primarily to the progress of projects and reclassification of some expenses due to organizational changes, etc., and general and administration expenses amounted to ¥11.0 billion (an increase of 23.6% year on year), due to an increase in various expenses including the enterprise tax (pro forma standard taxation).

As a result, Core operating profit was ¥78.7 billion (an increase of 32.0% year on year).

Other expense represents settlement for transfer pricing taxation to Roche, under which ¥1.1 billion was recorded in the nine months under review, including the deduction associated with the estimated amount recorded in the previous fiscal year.

As a result, core net income was ¥59.7 billion (an increase of 34.8% year on year).

**Note: Core results**

Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.

For further details regarding the adjustment to IFRS results, please refer to the Supplementary Materials on page 5, entitled "Reconciliation of IFRS results to Core results."

**Sales breakdown** in billions of yen

	First nine months of FY 2017.12 (Jan. 1, 2017–Sep. 30, 2017)	First nine months of FY 2016.12 (Jan. 1, 2016–Sep. 30, 2016)	% change
<b>Sales</b>	<b>364.8</b>	<b>347.5</b>	<b>+5.0</b>
<b>Domestic sales (excluding Tamiflu)</b>	<b>281.0</b>	<b>277.2</b>	<b>+1.4</b>
Oncology	163.5	161.2	+1.4
Bone and joint diseases	67.1	62.4	+7.5
Renal diseases	28.3	29.9	(5.4)
Others	22.0	23.8	(7.6)
<b>Tamiflu sales</b>	<b>10.0</b>	<b>8.4</b>	<b>+19.0</b>
Ordinary use	6.3	7.3	(13.7)
Government stockpiles	3.7	1.2	+208.3
<b>Overseas sales</b>	<b>73.8</b>	<b>61.8</b>	<b>+19.4</b>

**Domestic sales (excluding Tamiflu)**

Domestic sales excluding Tamiflu were ¥281.0 billion (an increase of 1.4% year on year) due to solid sales of mainstay products in the bone and joint diseases area, despite the impact of the previous year's NHI drug price revisions in the first quarter.

Oncology products sales were ¥163.5 billion (an increase of 1.4% year on year). This was due to the favorable performance of Alecensa (an ALK inhibitor, anti-cancer agent) and Perjeta (an anti-HER2 humanized monoclonal antibody, anti-cancer agent) outweighing the decrease in sales of mainstay products such as Avastin (an anti-VEGF humanized monoclonal antibody, anti-cancer agent), which became subjected to special market-expansion re-pricing in April last year.

Bone and joint diseases products sales were ¥67.1 billion (an increase of 7.5% year on year). This was due to the robust sales of mainstay products such as Ediro, a top brand in the domestic market of oral therapeutic agents for osteoporosis, Actemra (a humanized anti-IL-6 receptor monoclonal antibody) and Bonviva (a bisphosphonate for osteoporosis).

Renal diseases products sales amounted to ¥28.3 billion (a decrease of 5.4% year on year) due to a decline in sales of Oxarol (an agent for secondary hyperparathyroidism) and Mircera (a long-acting erythropoiesis-stimulating agent), as a result of the NHI drug price revisions in April last year.

**Tamiflu sales**

Sales of Tamiflu (an anti-influenza agent) for ordinary use were ¥6.3 billion (a decrease of 13.7% year on year), while sales to government stockpiles etc. were ¥3.7 billion (an increase of 208.3% year on year).

**Overseas sales**

Overseas sales amounted to ¥73.8 billion (an increase of 19.4% year on year) due mainly to increases in exports of Alecensa and Actemra to Roche.

**Note: Domestic sales (excluding Tamiflu)**

Independently disclosed sales of transplant, immunology and infectious diseases area up until FY 2016 were included and disclosed in sales of others area from the first quarter in FY 2017.

**(2) Consolidated financial position****Assets, liabilities, and net assets** in billions of yen

	September 30, 2017	December 31, 2016	% change
Movements of assets and liabilities			
Net working capital	263.7	258.5	+2.0
Long-term net operating assets	188.4	172.7	+9.1
<b>Net operating assets (NOA)</b>	<b>452.2</b>	<b>431.1</b>	<b>+4.9</b>
Net cash	208.1	204.9	+1.6
Other non-operating assets – net	14.3	10.5	+36.2
<b>Total net assets</b>	<b>674.6</b>	<b>646.5</b>	<b>+4.3</b>
Consolidated balance sheet (IFRS basis)			
Total assets	817.9	806.3	+1.4
Total liabilities	(143.4)	(159.8)	(10.3)
Total net assets	674.6	646.5	+4.3

Net working capital at September 30, 2017 was ¥263.7 billion (an increase of ¥5.2 billion since December 31, 2016). This was because the sum of the increase in accounts receivable-trade and decrease in accounts payable-trade outweighed the decrease in inventories. Long-term net operating assets increased by ¥15.7 billion since the end of the previous fiscal year to ¥188.4 billion, due mainly to an increase in property, plant and equipment. As a result, net operating assets (NOA) were ¥452.2 billion, an increase of ¥21.1 billion from the end of the previous fiscal year.

As the table entitled “Cash flows” on the next page indicates, net cash, including marketable securities and interest-bearing debt, increased by ¥3.2 billion since December 31, 2016 to ¥208.1 billion. Other non-operating assets - net increased by ¥3.8 billion from the end of the previous fiscal year to ¥14.3 billion, due mainly to a decrease in current income tax liabilities as a result of tax payment.

As a consequence, total net assets were ¥674.6 billion (an increase of ¥28.1 billion since December 31, 2016).

**Note: Movements of assets and liabilities**

The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, “Presentation of Financial Statements.” On the other hand, “Movements of assets and liabilities” including net operating assets (NOA) are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from the assets and liabilities have been excluded, as the Core results concept only applies to the income statement.

For further details, please refer to the Supplementary Materials on page 8, entitled “Movements of assets and liabilities.”

**Note: Net operating assets (NOA)**

Net operating assets allow for an assessment of the Group’s operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital, long-term net operating assets that includes property, plant and equipment, intangible assets etc. minus provisions.

**Cash flows** in billions of yen

	First nine months of FY 2017.12 (Jan. 1, 2017–Sep. 30, 2017)	First nine months of FY 2016.12 (Jan. 1, 2016–Sep. 30, 2016)	% change
<b>Movements of free cash flows</b>			
Operating profit - IFRS basis	76.2	58.6	+30.0
Operating profit, net of operating cash adjustments	90.5	72.6	+24.7
Operating free cash flows	56.2	31.3	+79.6
Free cash flows	31.1	10.5	+196.2
Net change in net cash	3.2	(26.8)	—
<b>Consolidated statement of cash flows (IFRS basis)</b>			
Cash flows from operating activities	68.8	43.8	+57.1
Cash flows from investing activities	(38.2)	(9.1)	+319.8
Cash flows from financing activities	(29.8)	(33.4)	(10.8)
Net change in cash and cash equivalents	2.2	(1.7)	—
Cash and cash equivalents at September 30	97.6	100.0	(2.4)

Operating profit, net of operating cash adjustments, amounted to ¥90.5 billion. This is calculated by adjusting for depreciation and other items that are included in operating profit but are not accompanied by cash inflows or outflows and all inflows and outflows related to NOA that are not accompanied by profit and loss. The principal items influencing this result were a total of ¥10.8 billion in depreciation of property, plant and equipment.

Operating free cash flows, which are calculated by adding a decrease in net working capital of ¥4.4 billion and also subtracting expenditures of ¥38.7 billion for the purchase of property, plant and equipment and intangible assets from operating profit, net of operating cash adjustments, amounted to a net inflow of ¥56.2 billion. Factors accounting for the decrease in net working capital are as shown on the previous page in the table entitled “Assets, liabilities, and net assets.” Purchases of property, plant and equipment were mainly expenditures for purchase of buildings and equipment of the laboratories and plants.

Free cash flows were a net cash inflow of ¥31.1 billion. This is calculated by subtracting a total of ¥25.1 billion of non-operating cash outflows from financial asset management, settlement for transfer pricing taxation and income taxes paid from operating free cash flows.

As a result, the net change in net cash, after dividends paid and foreign currency translation adjustments, was an increase of ¥3.2 billion in comparison with the end of the previous fiscal year. The net change in cash and cash equivalents, excluding changes in marketable securities and interest-bearing debt, was a net cash inflow of ¥2.2 billion. The cash and cash equivalents balance at the end of the third quarter amounted to ¥97.6 billion.

**Note: Movements of free cash flows (FCF)**

The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, “Statement of Cash Flows.” FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results concept only applies to the income statement.

For further details, please refer to the Supplementary Materials on page 9, entitled “Movements of free cash flows.”

**(3) Forecast for consolidated performance**

Chugai has not made any changes in its forecast of consolidated results for the fiscal year ending December 31, 2017 since the announcement regarding the forecast issued on February 1, 2017.

*Note: In “1. Qualitative Information,” amounts less than ¥0.1 billion have been rounded to the nearest ¥0.1 billion. Figures for changes in amounts and percentages have been calculated using data denominated in ¥0.1 billion units.*

## 2. Interim Condensed Consolidated Financial Statements and Major Notes

### (1) Interim condensed consolidated income statement and interim condensed consolidated statement of comprehensive income

#### 1) Interim condensed consolidated income statement in millions of yen

	First nine months ended September 30	
	2017	2016
<b>Revenues</b>	<b>387,645</b>	<b>361,517</b>
Sales	364,791	347,476
Royalties and other operating income	22,855	14,041
Cost of sales	(186,507)	(183,862)
<b>Gross profit</b>	<b>201,138</b>	<b>177,655</b>
Marketing and distribution	(49,181)	(49,883)
Research and development	(65,679)	(60,263)
General and administration	(10,046)	(8,874)
<b>Operating profit</b>	<b>76,233</b>	<b>58,635</b>
Financing costs	(90)	(68)
Other financial income (expense)	(193)	492
Other expense	(1,097)	—
<b>Profit before taxes</b>	<b>74,853</b>	<b>59,059</b>
Income taxes	(17,002)	(15,356)
<b>Net income</b>	<b>57,851</b>	<b>43,702</b>
Attributable to:		
Chugai shareholders	57,196	43,084
Non-controlling interests	655	618
Earnings per share		
Basic (yen)	104.66	78.89
Diluted (yen)	104.51	78.77



**2) Interim condensed consolidated statement of comprehensive income** in millions of yen

	First nine months ended September 30	
	2017	2016
<b>Net income recognized in income statement</b>	<b>57,851</b>	<b>43,702</b>
Other comprehensive income		
Remeasurements of defined benefit plans	—	(173)
<b>Items that will not be reclassified to the income statement</b>	<b>—</b>	<b>(173)</b>
Available-for-sale investments	49	(1,011)
Cash flow hedges	(2,774)	149
Currency translation of foreign operations	3,050	(6,687)
<b>Items that may be reclassified subsequently to the income statement</b>	<b>325</b>	<b>(7,549)</b>
<b>Other comprehensive income, net of tax</b>	<b>325</b>	<b>(7,722)</b>
<b>Total comprehensive income</b>	<b>58,177</b>	<b>35,980</b>
Attributable to:		
Chugai shareholders	57,436	35,529
Non-controlling interests	741	451

**(2) Interim condensed consolidated balance sheet** in millions of yen

	September 30, 2017	December 31, 2016
Assets		
Non-current assets:		
Property, plant and equipment	170,475	157,081
Intangible assets	21,207	19,299
Financial non-current assets	9,704	9,706
Deferred tax assets	30,529	27,474
Other non-current assets	14,377	13,965
<b>Total non-current assets</b>	<b>246,293</b>	<b>227,525</b>
Current assets:		
Inventories	177,742	185,440
Accounts receivable	168,518	167,482
Current income tax assets	673	1
Marketable securities	110,879	110,176
Cash and cash equivalents	97,582	95,368
Other current assets	16,258	20,293
<b>Total current assets</b>	<b>571,652</b>	<b>578,760</b>
<b>Total assets</b>	<b>817,945</b>	<b>806,285</b>
Liabilities		
Non-current liabilities:		
Long-term debt	(239)	(510)
Deferred tax liabilities	(9,201)	(9,146)
Defined benefit plan liabilities	(10,125)	(8,790)
Long-term provisions	(2,030)	(2,140)
Other non-current liabilities	(15,595)	(15,543)
<b>Total non-current liabilities</b>	<b>(37,190)</b>	<b>(36,128)</b>
Current liabilities:		
Short-term debt	(130)	(135)
Current income tax liabilities	(8,132)	(10,533)
Short-term provisions	(71)	(76)
Accounts payable	(58,054)	(72,346)
Other current liabilities	(39,810)	(40,570)
<b>Total current liabilities</b>	<b>(106,197)</b>	<b>(123,660)</b>
<b>Total liabilities</b>	<b>(143,387)</b>	<b>(159,788)</b>
<b>Total net assets</b>	<b>674,558</b>	<b>646,497</b>
Equity:		
Capital and reserves attributable to Chugai shareholders	673,772	645,508
Equity attributable to non-controlling interests	786	989
<b>Total equity</b>	<b>674,558</b>	<b>646,497</b>

**(3) Interim condensed consolidated statement of cash flows** in millions of yen

	First nine months ended September 30	
	2017	2016
Cash flows from operating activities		
Cash generated from operations	93,672	75,965
(Increase) decrease in working capital	4,388	(9,051)
Payments made for defined benefit plans	(1,913)	(1,820)
Utilization of provisions	(25)	(69)
Other operating cash flows	(5,513)	3,776
<b>Cash flows from operating activities, before income taxes paid</b>	<b>90,610</b>	<b>68,800</b>
Income taxes paid	(21,854)	(24,989)
<b>Total cash flows from operating activities</b>	<b>68,756</b>	<b>43,811</b>
Cash flows from investing activities		
Purchase of property, plant and equipment	(29,768)	(27,419)
Purchase of intangible assets	(8,932)	(4,838)
Disposal of property, plant and equipment	13	(178)
Interest and dividends received	157	189
Purchases of marketable securities	(161,468)	(161,832)
Sales of marketable securities	161,791	185,018
Other investing cash flows	(5)	(5)
<b>Total cash flows from investing activities</b>	<b>(38,212)</b>	<b>(9,065)</b>
Cash flows from financing activities		
Interest paid	(5)	(6)
Dividends paid to Chugai shareholders	(29,947)	(31,571)
Dividends paid to non-controlling shareholders	(944)	(1,105)
Exercise of equity compensation plans	575	420
(Increase) decrease in own equity instruments	(11)	(6)
Other financing cash flows	570	(1,107)
<b>Total cash flows from financing activities</b>	<b>(29,761)</b>	<b>(33,374)</b>
Net effect of currency translation on cash and cash equivalents	1,431	(3,031)
<b>Increase (decrease) in cash and cash equivalents</b>	<b>2,213</b>	<b>(1,659)</b>
Cash and cash equivalents at January 1	95,368	101,707
<b>Cash and cash equivalents at September 30</b>	<b>97,582</b>	<b>100,048</b>

**(4) Interim condensed consolidated statement of changes in equity** in millions of yen**For the first nine months ended September 30, 2016 (Jan. 1, 2016–Sep. 30, 2016)**

	Attributable to Chugai shareholders				Subtotal	Non-controlling interests	Total equity
	Share capital	Capital surplus	Retained earnings	Other reserves			
<b>At January 1, 2016</b>	<b>72,967</b>	<b>62,567</b>	<b>488,954</b>	<b>1,369</b>	<b>625,857</b>	<b>1,414</b>	<b>627,271</b>
Net income	—	—	43,084	—	43,084	618	43,702
Available-for-sale investments	—	—	—	(1,011)	(1,011)	—	(1,011)
Cash flow hedges	—	—	—	149	149	—	149
Currency translation of foreign operations	—	—	—	(6,520)	(6,520)	(167)	(6,687)
Remeasurements of defined benefit plans	—	—	(173)	—	(173)	—	(173)
<b>Total comprehensive income</b>	<b>—</b>	<b>—</b>	<b>42,911</b>	<b>(7,382)</b>	<b>35,529</b>	<b>451</b>	<b>35,980</b>
Dividends	—	—	(31,675)	—	(31,675)	(1,105)	(32,780)
Equity compensation plans	—	188	—	—	188	—	188
Own equity instruments	—	545	—	—	545	—	545
<b>At September 30, 2016</b>	<b>72,967</b>	<b>63,300</b>	<b>500,190</b>	<b>(6,013)</b>	<b>630,445</b>	<b>760</b>	<b>631,205</b>

**For the first nine months ended September 30, 2017 (Jan. 1, 2017–Sep. 30, 2017)**

	Attributable to Chugai shareholders				Subtotal	Non-controlling interests	Total equity
	Share capital	Capital surplus	Retained earnings	Other reserves			
<b>At January 1, 2017</b>	<b>72,967</b>	<b>63,500</b>	<b>507,399</b>	<b>1,642</b>	<b>645,508</b>	<b>989</b>	<b>646,497</b>
Net income	—	—	57,196	—	57,196	655	57,851
Available-for-sale investments	—	—	—	49	49	—	49
Cash flow hedges	—	—	—	(2,774)	(2,774)	—	(2,774)
Currency translation of foreign operations	—	—	—	2,964	2,964	86	3,050
Remeasurements of defined benefit plans	—	—	—	—	—	—	—
<b>Total comprehensive income</b>	<b>—</b>	<b>—</b>	<b>57,196</b>	<b>239</b>	<b>57,436</b>	<b>741</b>	<b>58,177</b>
Dividends	—	—	(30,055)	—	(30,055)	(944)	(30,998)
Equity compensation plans	—	110	—	—	110	—	110
Own equity instruments	—	773	—	—	773	—	773
<b>At September 30, 2017</b>	<b>72,967</b>	<b>64,383</b>	<b>534,540</b>	<b>1,882</b>	<b>673,772</b>	<b>786</b>	<b>674,558</b>

**(5) Notes regarding the going concern assumption**

None

**(6) Notes regarding the interim condensed consolidated financial statements****General accounting principles and significant accounting policies****(a) Basis of preparation of the consolidated financial statements**

These financial statements are the interim condensed consolidated financial statements (“Interim Financial Statements”) of Chugai, a company registered in Japan, and its subsidiaries (“the Group”). The common stock of Chugai is publicly traded and listed on the Tokyo Stock Exchange under the stock code “TSE: 4519.” The Interim Financial Statements were approved by the Board of Directors on October 25, 2017.

Roche Holding Ltd. is a public company registered in Switzerland and the parent company of the Roche Group, which discloses its results in accordance with IFRS. The shareholding percentage of Roche Holding Ltd. in Chugai is 59.89% (61.32% of the total number of shares issued excluding treasury stock). The Group became principal members of the Roche Group after entering into a strategic alliance in October 2002.

The Group meets all of the requirements for a “Specified Company under Designated International Financial Reporting Standards” as stipulated under Article 1-2 of the “Ordinance on Terminology, Forms, and Preparation Methods of Quarterly Consolidated Financial Statements” (Japanese Cabinet Ordinance No. 64, 2007). Hence, in accordance with Article 93 of the same Ordinance, the Interim Financial Statements have been prepared in accordance with International Accounting Standard (IAS) No. 34 “Interim Financial Reporting.”

The Interim Financial Statements should be used with the consolidated financial statements for the year ended December 31, 2016 as they do not include all the information as required for the consolidated financial statements for the full fiscal year.

The Interim Financial Statements are presented in Japanese yen, which is Chugai’s functional currency and amounts are rounded to the nearest ¥1 million. They have been prepared using the historical cost convention except for items that are required to be accounted for at fair value.

**(b) Key accounting judgments, estimates and assumptions**

The preparation of the Interim Financial Statements requires management to make judgments, estimates, and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, and contingent amounts. Actual outcomes could differ from those management estimates. The estimates and underlying assumptions are reviewed on an on-going basis and are based on historical experience and various other factors. Revisions to estimates are recognized in the period in which the estimate is revised.

The information for judgment, estimates, and assumptions that have a material impact on the amount recognized in the Interim Financial Statements of the Group is principally the same for the prior fiscal year.

**(c) Significant accounting policies**

The Group applies the same significant accounting policies that are used for the prior fiscal year’s consolidated financial statements to the Interim Financial Statements.